

# Exacerbation prevention in patients with both chronic obstructive pulmonary disease and obstructive sleep apnoea

<b>Submission date</b> 06/01/2025	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 20/01/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 10/04/2025	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Patients with chronic obstructive pulmonary disease-obstructive sleep apnoea (COPD-OSA) overlap syndrome have higher rates of COPD exacerbations compared to patients with similar severity COPD without OSA. It is currently unknown whether treating OSA in those with COPD-OSA overlap reduces COPD exacerbation rates. The randomised controlled trial will aim to determine whether giving PAP therapy to patients with COPD-OSA overlap will reduce exacerbations of COPD. Patients with COPD-OSA overlap will be randomised into one of two groups: a) PAP therapy in addition to usual care for COPD compared to b) Usual care for COPD alone.

### Who can participate?

Patients with moderate-severe COPD (GOLD grade 2-4), high risk of future exacerbations: 1 severe (hospital assessed) exacerbation or 2 moderate (community clinician assessed) in the last 12 months, and moderate-severe OSA (AHI  $\geq$  15/h)

### What does the study involve?

Participants will be randomised to receive home positive airway pressure (PAP) and COPD usual care or COPD usual care alone with a 12-month follow-up period with an internal pilot.

### Usual Care Arm:

If randomised to usual care the following information/advice and management will be delivered: as per NICE (<https://www.nice.org.uk/guidance/ng115/resources/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-66141600098245>) and local guidance. This will include as a minimum: a review of pharmacotherapy and consideration of regular, triple-inhaled bronchodilator therapy (long-acting  $\beta$ -agonist, long-acting anti-muscarinic, and steroid), antibiotic prophylaxis, as-needed inhaled short-acting  $\beta$ -agonist therapy, sputum clearance techniques where appropriate, smoking cessation support, pulmonary rehabilitation and education on COPD self-management including non-pharmacological management of COPD, including vaccination additionally advice on sleep quality will be given.

### Intervention Arm:

PAP therapy for participants in the intervention arm will be delivered according to local site clinical protocols. All centres involved in the study will be asked for SOPs as part of the process evaluation. Where SOPs are not available senior members of the team will be interviewed to understand the local pathway. As a minimum, the following would be expected for device setup:

1. Face-to-face assessment for mask fitting and device training
2. Mask fit and PAP tolerance check
3. Use of humidification according to patient preference and symptom tolerance
4. Remote review within 1st 30 days to check compliance, troubleshoot technical issues, review mask fit and leak

All participants will undergo face-to-face assessments at 3- and 12-months following randomisation and will complete outcome measures assessments. Trial visits will occur  $\pm$  14 days from the scheduled date. Telephone calls will be made monthly (a minimum of 3 attempts will be made over at least three days of the scheduled period of follow-up, after which this the visit will be classed as a missed visit) to collect health care utilisation and PAP therapy (if in the intervention group) data and will be verified at the face-to-face visits.

### What are the possible benefits and risks of participating?

Using PAP therapy may reduce participants' risk of having another flare-up of their breathing and improve sleep quality and quality of life. Taking part in the study will help us understand whether PAP therapy is or is not beneficial to patients with COPD and OSA who are at high risk of having repeated exacerbations of their COPD.

All patients taking part in the study will benefit from regular visits with the research team who are experienced in supporting patients with COPD.

There are no expected significant disadvantages to taking part. PAP therapy is used commonly in patients with OSA and severe sleepiness and is tolerated by the majority of patients. However, it can be difficult and uncomfortable for some patients and this is why it is important to understand the potential benefits so patients can make informed decisions on using the treatment. Common side effects are usually minor and include skin discomfort and a runny nose; these may resolve with simple steps, such as additional padding under the mask or a nose spray but also improve over time. If severe they may necessitate stopping PAP and the side effects will then stop. If you do experience any side effects from the machine, please contact your local research team using the telephone numbers on the last page of this leaflet.

Potential risks/side effects of PAP therapy include:

- Skin irritation: the mask can irritate the skin where it is applied. You will be provided with training to fit the mask appropriately to reduce this risk.
- Dry nose, mouth and eyes: The flow of air from the PAP device can sometimes cause drying of the nose, mouth or eyes. This is more common if there is a significant leak from the mask so it will be important to have training to reduce this. Participants will also be offered additional humidification of the air to reduce this problem. Rarely (<5%) nose bleeds can occur following starting PAP.
- Runny nose: It is common when starting PAP therapy to develop a runny nose. This is usually mild and resolves without any treatment but may need treatment with a nasal spray.
- Claustrophobia: Some people can find the mask claustrophobic.
- Swallowing air (called aerophagia): When using the machine, you can sometimes swallow some of the air causing burping or slight discomfort.

All patients receive current "best practice" therapy. All the tests involve little/no discomfort, other than the time taken to perform them. The blowing tests may feel uncomfortable as they require some effort but are safe.

This study will require time and commitment from the patients enrolled, which the research team appreciate and are very grateful for. There are three face-to-face study visits (at the start of the study, 3 months later and at the end of the study at 12 months). These face-to-face visits will take approximately 45 minutes. There are also monthly telephone calls which should take 10 minutes each. All participants will be closely followed up by the research team who are experienced in the management of patients with COPD and OSA.

The study will be under the guidance of a Trial Steering Committee whose job is to ensure that the study is managed well and to monitor safety.

Other potential risks of taking part in the study are felt to be low but could include:

- Distress if you are unable to comply with the PAP treatment or follow-up plans that are part of the trial
- Data risks: Data are collected about participants and their health. These data are collected and stored in line with data protection and clinical trial guidance to reduce the risks but data may be accessed by individuals not directly involved in your care or the trial.

Where is the study run from?

Sponsored by Guys and St Thomas Trust and Trial Management by the University of Oxford, Oxford Respiratory Trials Unit, UK

When is the study starting and how long is it expected to run for?

January 2024 to April 2028

Who is funding the study?

National Institute for Health and Care Research (NIHR), UK

Who is the main contact?

Dr Patrick Murphy, Patrick.Murphy@gstt.nhs.uk, epic-osa@ndm.ox.ac.uk

## Contact information

### Type(s)

Public

### Contact name

Dr Ellie Daly

### Contact details

Trial Manager  
ORTU - Churchill Hospital, University Of Oxford  
Old Road, Headington  
Oxford  
United Kingdom  
OX3 7LE  
+44 (0)1865 225205  
ellie.daly@ndm.ox.ac.uk

### Type(s)

Principal investigator

### Contact name

Dr Patrick Murphy

**ORCID ID**

<https://orcid.org/0000-0002-1500-611X>

**Contact details**

Consultant in Sleep, Ventilation and Respiratory Medicine  
Lane Fox Respiratory Unit  
Ground Floor, South Wing, Block C  
St Thomas' Hospital  
Westminster Bridge Road  
London  
United Kingdom  
SE1 7EH  
+44 (0)20 7188 7727  
Patrick.Murphy@gstt.nhs.uk

**Type(s)**

Scientific

**Contact name**

Dr Swapna Mandal

**ORCID ID**

<https://orcid.org/0000-0002-2232-5880>

**Contact details**

FRCP Consultant Respiratory Medicine Clinical Lead- Sleep and Ventilation Service  
Royal Free London NHS Foundation Trust  
Pond Steet  
London  
United Kingdom  
NW3 2QG  
+44 (0)7387586126  
swapnamandal@nhs.net

**Additional identifiers**

**Clinical Trials Information System (CTIS)**

Nil known

**Integrated Research Application System (IRAS)**

332000

**Protocol serial number**

CPMS 65205, NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC) Grant Code:  
NIHR154890

**Study information**

## Scientific Title

Exacerbation prevention in chronic obstructive pulmonary disease (COPD) – obstructive sleep apnoea (OSA) overlap syndrome: The clinical and health economic impact of treating patients with COPD-OSA overlap syndrome and a high risk of future exacerbations with positive airway pressure therapy (PAP) a multicentre randomised controlled trial

## Acronym

EPIC-OSA

## Study objectives

Patients with chronic obstructive pulmonary disease-obstructive sleep apnoea (COPD-OSA) overlap syndrome have higher rates of COPD exacerbations compared to patients with similar severity COPD without OSA. It is currently not known whether treating OSA in those with COPD-OSA overlap reduces exacerbation rates. COPD exacerbations are characterised by acute transient worsening of symptoms such as dyspnoea, sputum production, sputum purulence and cough which are above the normal day to day variation in symptom burden and are usually associated with escalation of medical therapy. Exacerbations are significant events impacting on patient's quality of life, lung function, future exacerbation risk and survival. Exacerbations are recognised as a significant concern by patients, with exacerbation prevention ranked as the number one research priority by COPD patients. The study aims to determine whether giving PAP (positive airway pressure) therapy to patients with COPD-OSA overlap will reduce exacerbations of COPD. A randomised controlled trial will be undertaken, patients with COPD-OSA overlap will be randomised to one of two groups: a) PAP therapy in addition to usual care for COPD, b) usual care for COPD alone.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

approved 24/12/2024, London - Westminster Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8066; westminster.rec@hra.nhs.uk), ref: 24/LO/0818

## Study design

Randomized controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Respiratory

## Interventions

This is a multi-centre randomised controlled trial in patients with COPD-OSA overlap and a high risk of exacerbations. Participants will be randomised via a web-based, pre-programmed randomisation system with minimisation for Epworth sleepiness score (<11 or ≥11), current long-term oxygen therapy use (Y/N) and study site, to receive home PAP and usual COPD care or usual COPD care alone with a 12-month follow-up period.

Several methods will be used to identify patients. Patients will be identified by clinical teams when attending clinical review in COPD clinics, rehabilitation services or sleep clinics. Where appropriate, patients who have attended community diagnostic centres for spirometry and have results consistent with COPD will be screened. Lastly, where possible local screening databases will be used to identify additional patients with COPD. Where possible clinical teams will be asked to record STOP-BANG and Epworth Sleepiness Score (ESS), if this is not feasible at the clinical visit, this will be done at screening. If patients meet the inclusion requirement they will be asked to consent to the study and undergo a sleep study. Following the sleep study patients with moderate to severe OSA will be randomised to PAP therapy or usual care.

At baseline assessment (visit 1) medical history, drug history and COPD clinical history will be recorded. Participants will also be asked to complete questionnaires including CAT, EQ-5D-5L, eMRCd score, Pittsburgh sleep quality index and Epworth Sleepiness Score. Spirometry (lung function testing) will also be undertaken.

Participants will then be reviewed at 3 and 12 months and all of the assessments in the baseline visit are repeated. In addition, PAP usage data will be recorded as well and any support for PAP therapy will be given.

Participants will also be contacted every month to:

1. Record health care utilisation
2. Exacerbations (number and treatment given)
3. Medication changes
4. Use of PAP therapy and if any support is required with this
5. Record any adverse or serious adverse events
6. Participants will also be asked to complete questionnaires including CAT, EQ-5D-5L, eMRCd score

## **Intervention Type**

Procedure/Surgery

## **Primary outcome(s)**

Exacerbation frequency measured using exacerbation frequency 12 months post-randomisation data collected by the hospital, community and self-treated at randomisation, baseline to 12 months

## **Key secondary outcome(s)**

Secondary outcome measures

1. The impact of 12 months of PAP therapy on quality of Life measured using the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score, extended MRC-Dyspnoea (eMRCd) score and 5-level EQ-5D version (EQ-5D-5L) at randomisation, baseline and 12 months
2. The impact of 12 months of PAP therapy on patient-reported sleep quality and daytime sleepiness measured using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Score (ESS) at randomisation, baseline and 3 and 12 months
3. The impact of 12 months of PAP therapy on Lung Function measured using Spirometry at randomisation, baseline and 3 and 12 months
6. The dose-response relationship between hours of PAP use and primary and secondary outcomes measured using usage hours downloaded from the PAP device, exacerbation frequency, patient-reported questionnaires (CAT, EQ5D5L, eMRCd, ESS, PSQI), spirometry, and healthcare utilisation at randomisation, baseline and 3 and 12 months (intervention group only)

7. The cost-effectiveness of PAP treatment in patients with COPD-OA overlap in the UK health system over 12 months measured using data collected regarding healthcare utilisation and EQ5D5L at randomisation, baseline and 12 months

### Exploratory

To explore the relationship between primary outcome and health-related quality of life based on COPD clinical phenotypes the following outcome variables will be assessed using participant characteristics, primary and secondary outcomes (exacerbation frequency, patient-reported questionnaires (CAT, EQ5D5L, eMRCQ, ESS, PSQI), spirometry, healthcare utilisation) at randomisation, baseline and 12 months:

1. Significant sleepiness (defined as an ESS  $\geq$  11),
2. Poor Sleep quality (defined as PSQI  $>$ 5)
3. GOLD ABE grouping
4. Eosinophilic COPD (yes/no)
5. Bronchitic COPD (yes/no)

### Completion date

13/04/2028

## Eligibility

### Key inclusion criteria

1. Moderate-severe COPD (GOLD grade 2-4)
2. High risk of future exacerbations: 1 severe (hospital assessed) exacerbation or 2 moderate (community clinician assessed) in the last 12 months
3. Moderate-severe OSA (AHI  $\geq$  15/h)

### Participant type(s)

Patient

### Healthy volunteers allowed

No

### Age group

Adult

### Sex

All

### Key exclusion criteria

1. Clinically significant or severe daytime sleepiness: Epworth Sleepiness score  $>$  15 or excessive sleepiness likely to impair safe driving in current drivers (as evidence has already established that such patients should be treated with PAP therapy)
2. Significant hypercapnic respiratory failure at baseline assessment (PaCO<sub>2</sub>  $>$  6kPa, with evidence already indicating these patients should be treated with NIV)
3. PAP therapy mandated by the treating clinician due to the severity of the sleep symptom burden
4. Professional driver or other vigilance essential role with significant daytime sleepiness
5. Currently enrolled in an interventional clinical trial

### Date of first enrolment

01/03/2025

**Date of final enrolment**

31/10/2026

**Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**St Thomas' Hospital (Leading sponsor site)**

Guy's and St Thomas' NHS foundation trust

Westminster Bridge Road

London

United Kingdom

SE1 7EH

**Study participating centre**

**Royal Free Hospital**

Royal Free London NHS Foundation Trust

Pond Street

London

United Kingdom

NW3 2QG

**Study participating centre**

**Freeman Hospital**

Newcastle Upon Tyne Hospitals NHS Foundation Trust

Freeman Road

High Heaton

Newcastle upon Tyne

United Kingdom

NE7 7DN

**Study participating centre**

**John Radcliffe Hospital**

Oxford University Hospitals NHS Foundation Trust

Headley Way

Headington

Oxford

United Kingdom  
OX3 9DU

**Study participating centre**

**James Cook University Hospital**

South Tees Hospitals NHS Foundation Trust  
Marton Road  
Middlesbrough  
Cleveland  
United Kingdom  
TS3 4BW

**Study participating centre**

**St Bartholomew's Hospital**

Barts Health NHS Trust  
West Smithfield  
London  
United Kingdom  
EC1A 7BE

**Study participating centre**

**Birmingham Heartlands Hospital**

University Hospitals Birmingham NHS Foundation Trust  
Bordesley Green East  
Birmingham  
United Kingdom  
B9 5SS

**Study participating centre**

**Gloucestershire Royal Hospital**

Gloucestershire Hospitals NHS Foundation Trust  
Great Western Road  
Gloucester  
United Kingdom  
GL1 3NN

**Study participating centre**

**Pinderfields General Hospital**

Mid Yorkshire Teaching NHS Trust  
Aberford Road  
Wakefield

United Kingdom  
WF1 4DG

**Study participating centre**

**St James's Hospital**

Leeds Teaching Hospitals NHS Trust  
Beckett Street  
Leeds  
United Kingdom  
LS9 7TF

**Study participating centre**

**Northern General Hospital**

Sheffield Teaching Hospitals NHS Foundation Trust  
Herries Road  
Sheffield  
United Kingdom  
S5 7AU

## Sponsor information

**Organisation**

Guy's and St Thomas' NHS Foundation Trust

**ROR**

<https://ror.org/00j161312>

## Funder(s)

**Funder type**

Government

**Funder Name**

National Institute for Health and Care Research

**Alternative Name(s)**

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol file</a>	version 1.0	14/10/2024	13/01/2025	No	No